A phase III randomized controlled clinical trial evaluating the efficacy and safety of naftifine 2% cream versus terbinafine 1% cream in patients with superficial fungal infection of the skin
DOI:
https://doi.org/10.18203/issn.2455-4529.IntJResDermatol20241599Keywords:
Dermatophytosis, Naftifine, Terbinafine, Superficial skin fungal infection, Topical antifungalsAbstract
Background: Dermatophytosis is the prevailing fungal infection, typically addressed through topical, systemic antifungal medications, or a combination of both. Naftifine hydrochloride, belonging to the allylamine group, is a topical antifungal, exhibiting fungicidal properties alongside antibacterial and anti-inflammatory effects. This study evaluated the efficacy and safety of naftifine hydrochloride 2% w/w in 268 patients with dermatophytosis versus terbinafine hydrochloride 1% w/w.
Methods: The drugs were applied daily for two weeks, with the primary endpoint being a clinical cure at the end of the treatment. Secondary endpoints included mycological cure, composite cure, global efficacy assessment, and post-treatment relapse.
Results: In both groups, most patients experienced both clinical and mycological cures, with composite cures observed in 94.07% of the test group and 87.97% of the reference group. The global assessment of efficacy was 3.59 in the test group and 3.48 in the reference group, showing no notable difference between the two groups. All adverse events in both groups were mild and resolved within four days. Overall tolerability was comparable between the study groups.
Conclusions: The study concluded that topical naftifine was effective and safe in patients with dermatophytosis and its efficacy and safety were found comparable to topical terbinafine.
Metrics
References
Ganeshkumar P, Mohan Sr, Hemamalini M, Madhavan R, Lakshmanan A. Epidemiological and clinical pattern of dermatomycoses in rural India. Indian J Med Microbiol. 2015;33:134-40.
Prabha ML, Meenakshi B, Devi PN, Ramya JE, Balan CR. A randomized comparative study to assess the efficacy of topical luliconazole versus topical clotrimazole in tinea corporis and tinea cruris. Natl J Physiol Pharm Pharmacol. 2019; 9:756-62.
Jerajani HR, Janaki C, Kumar S, Phiske M. Comparative assessment of the efficacy and safety of sertaconazole (2%) cream versus terbinafine cream (1%) versus luliconazole (1%) cream in patients with dermatophytoses: A pilot study. Indian J Dermatol. 2013;58:34-8.
Das A, Sil A, Sarkar TK, Sen A, Chakravorty S, Sengupta M, et al. A randomized, double-blind trial of amorolfine 0.25% cream and sertaconazole 2% cream in limited dermatophytosis. Indian J Dermatol Venereol Leprol. 2019;85:276-81.
Sahni K, Singh S, Dogra S. Newer Topical Treatments in Skin and Nail Dermatophyte Infections. Indian Dermatol Online J. 2018;9:149-58.
Chatterjee D, Ghosh SK, Sen S, Sarkar S, Hazra A, De R. Efficacy and tolerability of topical sertaconazole versus topical terbinafine in localized dermatophytosis: A randomized, observer-blind, parallel group study. Indian J Pharmacol. 2016;48: 659-64.
Banerjee M, Ghosh AK, Basak S, Das KD, Gangopadhyay DN. Comparative evaluation of effectivity and safety of topical amorolfine and clotrimazole in the treatment of tinea corporis. Indian J Dermatol 2011;56:657-62.
Naftifine Hydrochloride cream, 2%, for topical use. Available at: https://www.drugs.com/pro/naftifine-cream.html. Accessed on 20 January 2024.
NAFTIN gel for topical use. Available at: https://sebelapharma.com/assets/media/our-products/naftingel-pi.pdf. Accessed on 20 January 2024.
NAFTIN. Available at: https://dailymed.nlm.nih.gov/ dailymed/drugInfo.cfm?setid=f4b6c5d8-615c-47d6-8ad9-523c7ab146af. Accessed on 20 January 2024.
Thompson AJ, Tyring SK. Naftifine HCl 2% Cream for the treatment of Tinea Pedis: A Review. Curr Dermatol Rep. 2013;2:191-3.
Gupta AK, Ryder JE, Cooper EA. Naftifine: a review. J Cutan Med Surg. 2008;12:51-8.
Del Rosso JQ, Kircik LH. Optimizing topical antifungal therapy for superficial cutaneous fungal infections: focus on topical naftifine for cutaneous dermatophytosis. J Drugs Dermatol. 2013;12:165-71.
Parish LC, Parish JL, Routh HB, Fleischer AB Jr, Avakian EV, Plaum S, et al. A randomized, double-blind, vehicle-controlled efficacy and safety study of naftifine 2% cream in the treatment of tinea pedis. J Drugs Dermatol. 2011;10:1282-8.
Parish LC, Parish JL, Routh HB, Avakian E, Olayinka B, Pappert EJ, et al. A double-blind, randomized, vehicle-controlled study evaluating the efficacy and safety of naftifine 2% cream in tinea cruris. J Drugs Dermatol. 2011;10:1142-7.
Chandana T, Saritha C, Shankaraiah P. Comparison of safety and efficacy of laliconazole and other antifungal agents. Int J Pharma Res Health Sci. 2014;5:1-9.
Chatterjee D, Ghosh SK, Sen S, Sarkar S, Hazra A, De R. Efficacy and tolerability of topical sertaconazole versus topical terbinafine in localized dermatophytosis: A randomized, observer-blind, parallel-group study. Indian J Pharmacol. 2016;48:659-64.
Borelli C, Klövekorn G, Ernst TM, Bödeker RH, Korting HC, Neumeister C. Comparative study of 2% sertaconazole solution and cream formulations in patients with tinea corporis, tinea pedis interdigitalis, or a corresponding candidosis. Am J Clin Dermatol. 2007;8:371-8.
de Chauvin MF, Viguié-Vallanet C, Kienzler JL, Larnier C. Novel, single-dose, topical treatment of tinea pedis using terbinafine: results of a dose-finding clinical trial. Mycoses. 2008;51:1-6.
Jartarkar SR, Patil A, Goldust Y, Cockerell CJ, Schwartz RA, Grabbe S, et al. Pathogenesis, Immunology and Management of Dermatophytosis. J Fungi. 2022;8:39.
Dogra S, Uprety S. The menace of chronic and recurrent dermatophytosis in India: is the problem deeper than we perceive? Indian Dermatol Online J. 2016;7:73-6.
Dogra S. Difficult dermatophytosis. JAMA Dermatol. 2022;158:1243-4.
Stefan P, Amit V, Fleischer AB. Detection and relevance of naftifine hydrochloride in the stratum corneum up to four weeks following the last application of naftifine cream and gel, 2%. J Drugs Dermatol. 2013;12:1004-8.
AL-Khikani FHO, Ayit AS. Major challenges in dermatophytosis treatment: current options and future visions. Egypt J Dermatol Venerol. 2021;41:1-9.
Gupta AK, Mays RR, Foley KA. Topical Antifungal Agents. Comprehensive Dermatol Drug Ther. 2021;12:480-92.
